Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
Andrea ContiF PeccerilloP AmerioAnna BalatoF BardazziL BianchiM BurlandoS P CannavòAndrea ChiricozziP DapavoC De SimoneM C FargnoliA GambardellaPaolo GisondiP MalagoliG MalaraC MughedduA M OffidaniS PiasericoFrancesca PrignanoL StingeniG PellacaniPublished in: The British journal of dermatology (2019)